Page last updated: 2024-11-02

pd 98059 and Dysmyelopoietic Syndromes

pd 98059 has been researched along with Dysmyelopoietic Syndromes in 2 studies

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
da Costa, SV1
Roela, RA1
Junqueira, MS1
Arantes, C1
Brentani, MM1
Koschmieder, S1
Hofmann, WK1
Kunert, J1
Wagner, S1
Ballas, K1
Seipelt, G1
Hoelzer, D1
Ottmann, OG1
Kalina, U1

Other Studies

2 other studies available for pd 98059 and Dysmyelopoietic Syndromes

ArticleYear
The role of p38 mitogen-activated protein kinase in serum-induced leukemia inhibitory factor secretion by bone marrow stromal cells from pediatric myelodysplastic syndromes.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Anthracenes; Bone Marrow Cells; Cells, Cultured; Child; Child, Preschool; Female; Flavonoids; Humans

2010
TGF beta-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS.
    Leukemia, 2001, Volume: 15, Issue:6

    Topics: Acute Disease; Adult; Antigens, CD34; Cell Division; Disease Progression; DNA Replication; DNA-Bindi

2001